Whalesbook
Solara Active Pharma Sciences has increased its paid-up capital to ₹4,798.12 crore following the recent allotment of 2,200 equity shares. The company's paid-up capital stood at ₹4,451.39 crore prior to this issuance.
The shares were issued under the company's Employee Stock Option Plan 2018. The allotment was made at an exercise price of ₹309 per share, generating ₹8.37 lakh for Solara. These newly issued shares will carry the same rights as existing equity shares. The allotment is estimated to impact diluted Earnings Per Share (EPS) by ₹2.23 per share.
This share issuance is part of Solara's strategy to incentivize its employees, aligning their interests with the company's long-term growth. While the increase in capital is modest in scale relative to the company's total, it does result in a slight dilution for existing shareholders.
Solara Active Pharma Sciences is a global pharmaceutical company focused on Active Pharmaceutical Ingredients (APIs) and contract manufacturing services, with operations in India and Italy. Its ESOP 2018 was established to foster employee engagement and reward performance. The company has a history of utilizing ESOP allotments as part of its employee incentive framework.
The issuance expands the shareholder equity base slightly and increases the total number of outstanding shares, leading to fractional dilution. Employees who received shares under the ESOP plan now gain voting rights and are entitled to dividends. The company's reported paid-up capital figure has been updated to reflect these changes.
In the competitive pharmaceutical sector, peers such as Divi's Laboratories, Aarti Drugs, and Laurus Labs also use ESOPs to attract and retain talent. These companies, active in the API and CDMO space, similarly manage their capital structure and shareholder base through such mechanisms.
As of May 15, 2026, the company's consolidated paid-up capital stood at ₹4,798.12 crore. The funds realized from the share exercise on the same date were ₹0.08 crore. The estimated diluted EPS impact of ₹2.23 per share is projected for FY27. The exercise price for these shares under ESOP 2018 was ₹309.
Investors will likely monitor future ESOP grants and their potential dilution effects. The company's broader employee compensation strategy and its effectiveness, alongside performance in its core API and CDMO businesses, will also be points of focus.